Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 7, 1998, Pages 617-622

  Salomon, O ^a   Moisseiev, J ^a   Rosenberg, N ^a   Vidne, O ^a   Yassur, I ^a   Zivelin, A ^a   Treister, G ^a   Steinberg, D M ^b   Seligsohn, U ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

APCR; Apolipoprotein E4; Factor II G20210A; Factor V R506Q; MTHRF C677T

Indexed keywords

APOLIPOPROTEIN E4; BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RISK FACTOR; THROMBOGENESIS; THROMBOSIS;

EID: 0031797826     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199810000-00008     Document Type: Article

References (31)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247.
2. Fong ACO, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, et al. Central retinal vein occlusion in young adults (papillophlebitis). Retina 1991; 12: 3-11.
3. The eye disease case-control study group. Risk factors for central retinal vein occlusion. Arch Opthalmol 1996; 114: 545-554.
4. McGrath MA, Wechsler F, Hunyor ABL, Penny R. Systemic factors contributory for retinal vein occlusion. Arch Int Med 1978; 138: 216-220.
5. Larsson J, Olafsdottir E, Bauer B. Activated protein resistance in young adults with central retinal vein occlusion. Br J Opthalmol 1996; 80: 200-202.
6. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Opthalmol 1996; 80: 203-208.
7. Hodgkins PR, Perry DJ, Sawcer SJ, Keast-Butler J. Factor V and antithrombin gene mutations in patients with idiophatic central retinal vein occlusion. Eye 1995; 9: 760-762.
8. Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T. Prevalence of factor V Leiden in young adults with retinal vein occulsion. Thromb Haemost 1997; 77: 214-216.
9. Wenzler EM, Rademakers AJJ, Boers GHJ, Cruysberg JRM, Webers CAB, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Opthalmol 1993; 115: 162-167.
10. Frosst P, Blom J, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
11. Engbersen AMT, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-150.
12. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
13. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocystememia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
14. de Franchis R, Mancini FPP, D'Angelo A, Sebastio G, Fermo I, de Stefano V. Elevated total plasma homocysteine and 677C → T mutation of the 5,10 methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262-264.
15. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi Jr, Costa FF. The mutation Ala677→Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-821.
16. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism and risk of myocardial infarction in the U.S. physicians. Circulation 1996; 94: 2410-2416.
17. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-258.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood 1996; 88: 3698-3703.
19. The eye disease case-control study group. Risk factors for branch retinal vein occlusion. Am J Opthalmol 1993; 116: 286-296.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure of extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
21. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood 1996; 88: 877-880.
22. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U. Improved method for the genotyping of the apolipoprotein K polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 1997; 43: 1657-1659.
23. Soni KG, Woodhouse DF. Retinal vascular occlusion as a presenting feature of glaucoma simplex. Br J Opthalmol 1971; 55: 192-195.
24. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197: 69-74.
25. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease probably benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
26. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Eng J Med 1996; 334: 759-762.
27. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects and folic acid. Am J Hum Genet 1996; 58: 17-20.
28. D'Angelo D, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
29. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotype. Atheroscler Thromb Vasc Biol 1997; 17: 1157-1162.
30. Seligsohn LJ, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
31. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996; 19: 171-178.